EP Patent

EP3728284B1 — 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders

Assigned to Sage Therapeutics Inc · Expires 2024-08-21 · 2y expired

What this patent protects

Patent listed against Zurzuvae.

Drugs covered by this patent

Zurzuvae (ZURANOLONE) · Biogen

Patent Metadata

Patent number: EP3728284B1
Jurisdiction: EP
Classification: —
Expires: 2024-08-21
Drug substance claim: No
Drug product claim: No
Assignee: Sage Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.